Janssen Research & Development, LLC $JNJ
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS112
PHASE 3 / 2-375
RECRUITING46
READOUTS ≤12 MONTHS26
READOUT SLIPPED >6 MO40%
Delay Index: of 90 active trials registered more than a year ago, 36 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.8 months). See all sponsors →
Open Janssen Research & Development, LLC on the live radar map → 📅 $JNJ readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| GLOW NCT03462719 |
P3 | Active, not recruiting | Leukemia, Lymphocytic, Chronic, B-Cell | 211 | 2021-02-26 |
| QUEST NCT03431350 |
P2 | Active, not recruiting | Prostatic Neoplasms, Castration-Resistant | 136 | 2021-08-31 (+25 mo) |
| MAGNITUDE NCT03748641 |
P3 | Active, not recruiting | Castration-Resistant Prostatic Cancer | 765 | 2021-10-08 (-9 mo) |
| MajesTEC-1 NCT04557098 |
P2 | Active, not recruiting | Hematological Malignancies | 194 | 2021-11-09 (-3 mo) |
| Erdafitinib NCT02365597 |
P2 | Active, not recruiting | Urothelial Cancer | 239 | 2022-09-15 (+79 mo) |
| Erdafitinib NCT03473743 |
P1/2 | Active, not recruiting | Urothelial Carcinoma | 125 | 2022-09-30 (+35 mo) |
| PAPILLON NCT04538664 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 308 | 2023-05-03 (+16 mo) |
| GRAVITI NCT05197049 |
P3 | Active, not recruiting | Crohn Disease | 350 | 2023-07-04 |
| MARIPOSA-2 NCT04988295 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 776 | 2023-07-10 (+1 mo) |
| PROTOSTAR NCT03451851 |
P3 | Active, not recruiting | Psoriasis | 120 | 2023-07-19 (+6 mo) |
| MARIPOSA NCT04487080 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 1074 | 2023-08-11 (-9 mo) |
| QUASAR NCT04033445 |
P2/3 | Active, not recruiting | Ulcerative Colitis | 1064 | 2023-09-19 (+15 mo) |
| GALAXI NCT03466411 |
P2/3 | Active, not recruiting | Crohn's Disease | 1409 | 2023-10-20 (+17 mo) |
| JNJ-63723283 NCT02908906 |
P1/2 | Active, not recruiting | Neoplasms | 234 | 2023-11-17 (+56 mo) |
| Nipocalimab NCT04951622 |
P3 | Recruiting | Myasthenia Gravis | 199 | 2023-11-17 |
| PURSUIT 2 NCT03596645 |
P3 | Active, not recruiting | Colitis, Ulcerative | 84 | 2023-11-21 (+23 mo) |
| PALOMA-3 NCT05388669 |
P3 | Active, not recruiting | Advanced or Metastatic Non-small Cell Lung Cancer | 418 | 2024-01-03 |
| Dexamethasone NCT05663866 |
P2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 68 | 2024-03-29 (-2 mo) |
| ASTRO NCT05528510 |
P3 | Active, not recruiting | Colitis, Ulcerative | 418 | 2024-04-02 (-1 mo) |
| THOR NCT03390504 |
P3 | Active, not recruiting | Urothelial Cancer | 629 | 2024-04-15 |
| CARTITUDE-4 NCT04181827 |
P3 | Active, not recruiting | Multiple Myeloma | 419 | 2024-05-01 (-23 mo) |
| ICONIC-TOTAL NCT06095102 |
P3 | Active, not recruiting | Plaque Psoriasis | 311 | 2024-06-19 (-5 mo) |
| ICONIC-LEAD NCT06095115 |
P3 | Active, not recruiting | Plaque Psoriasis | 684 | 2024-07-29 (-4 mo) |
| JNJ-77242113 NCT06143878 |
P3 | Active, not recruiting | Plaque Psoriasis | 774 | 2024-09-17 (-6 mo) |
| JNJ-77242113 NCT06220604 |
P3 | Active, not recruiting | Plaque Psoriasis | 731 | 2024-11-15 (-5 mo) |
| APEX NCT04882098 |
P3 | Active, not recruiting | Arthritis, Psoriatic | 1054 | 2024-12-30 (+12 mo) |
| AMPLITUDE NCT04497844 |
P3 | Active, not recruiting | Prostatic Neoplasms | 696 | 2025-01-07 (+2 mo) |
| ENERGY NCT04119050 |
P2/3 | Active, not recruiting | Warm Autoimmune Hemolytic Anemia | 118 | 2025-02-02 (+44 mo) |
| RedirecTT-1 NCT04586426 |
P1/2 | Active, not recruiting | Multiple Myeloma | 228 | 2025-03-18 (+41 mo) |
| DUET-UC NCT05242484 |
P2 | Active, not recruiting | Colitis, Ulcerative | 577 | 2025-05-15 (+9 mo) |
| DUET-CD NCT05242471 |
P2 | Active, not recruiting | Crohn's Disease | 703 | 2025-05-23 (+9 mo) |
| SunRISe-1 NCT04640623 |
P2 | Active, not recruiting | Urinary Bladder Neoplasms | 220 | 2025-07-03 (+8 mo) |
| MajesTEC-3 NCT05083169 |
P3 | Active, not recruiting | Multiple Myeloma | 587 | 2025-08-01 (+6 mo) |
| MajesTEC-9 NCT05572515 |
P3 | Active, not recruiting | Multiple Myeloma | 614 | 2025-10-13 (+2 mo) |
| ICONIC-ASCEND NCT06934226 |
P3 | Active, not recruiting | Plaque Psoriasis | 752 | 2025-11-17 (-24 mo) |
| AQUARIUS NCT05250973 |
P2 | Active, not recruiting | Amyloidosis | 151 | 2026-02-04 (+14 mo) |
| MonumenTAL-6 NCT06208150 |
P3 | Active, not recruiting | Multiple Myeloma | 838 | 2026-04-01 (-14 mo) |
| ICONIC-PsA 1 NCT06878404 |
P3 | Active, not recruiting | Arthritis, Psoriatic | 552 | 2026-05-25 (-4 mo) |
| LIBERTAS NCT05884398 |
P3 | Active, not recruiting | Metastatic Castrate-sensitive Prostate Cancer | 420 | 2026-10-12 (-8 mo) |
| LIBREXIA-STROK NCT05702034 |
P3 | Active, not recruiting | Ischemic Stroke; Ischemic Attack, Transient | 12523 | 2026-10-15 |
| READY-AD NCT07230860 |
P2 | Active, not recruiting | Dermatitis, Atopic | 189 | 2026-11-19 |
| PROTEUS NCT03767244 |
P3 | Active, not recruiting | Prostatic Neoplasms | 2517 | 2026-12-01 (+31 mo) |
| LIBREXIA-AF NCT05757869 |
P3 | Active, not recruiting | Atrial Fibrillation | 20284 | 2026-12-08 (-3 mo) |
| Nipocalimab NCT05327114 |
P2/3 | Recruiting | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 201 | 2026-12-15 (+7 mo) |
| SunRISe-2 NCT04658862 |
P3 | Active, not recruiting | Urinary Bladder Neoplasms | 518 | 2026-12-30 |
| Seltorexant NCT06559306 |
P3 | Recruiting | Depressive Disorder, Major | 752 | 2026-12-30 |
| CAN3001 NCT01804686 |
P3 | Active, not recruiting | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | 539 | 2026-12-31 |
| PolyDamas NCT05908734 |
P1/2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 71 | 2027-01-31 (+19 mo) |
| DAFFODIL NCT06741969 |
P3 | Active, not recruiting | Sjogrens Syndrome | 655 | 2027-02-04 (-11 mo) |
| QUASAR Jr NCT06260163 |
P3 | Active, not recruiting | Colitis, Ulcerative | 112 | 2027-02-10 (-15 mo) |
| ICONIC-PsA 2 NCT06807424 |
P3 | Active, not recruiting | Arthritis, Psoriatic | 813 | 2027-02-10 |
| CARTITUDE-2 NCT04133636 |
P2 | Active, not recruiting | Multiple Myeloma | 208 | 2027-02-26 (+59 mo) |
| OrigAMI-1 NCT05379595 |
P1/2 | Recruiting | Advanced or Metastatic Colorectal Cancer | 225 | 2027-04-27 (+6 mo) |
| METalmark NCT05488314 |
P1/2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 57 | 2027-04-28 (+28 mo) |
| COCOON NCT06120140 |
P2 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 305 | 2027-05-31 (+26 mo) |
| TRIlogy-3 NCT07266441 |
P2 | Active, not recruiting | Multiple Myeloma | 168 | 2027-06-14 |
| VELOTA NCT07321873 |
P2 | Active, not recruiting | Arthritis, Psoriatic | 157 | 2027-06-28 |
| Nipocalimab NCT05265273 |
P2/3 | Recruiting | Myasthenia Gravis | 12 | 2027-06-30 (+27 mo) |
| MonumenTAL-1 NCT04634552 |
P2 | Recruiting | Hematological Malignancies | 510 | 2027-06-30 (+45 mo) |
| MonumenTAL-3 NCT05455320 |
P3 | Active, not recruiting | Multiple Myeloma | 864 | 2027-07-30 (+18 mo) |
| AZALEA NCT05912517 |
P3 | Recruiting | Hemolytic Disease of the Fetus and Newborn | 120 | 2027-08-05 |
| PALOMA-2 NCT05498428 |
P2 | Recruiting | Carcinoma, Non-small-Cell Lung | 520 | 2027-08-17 (+39 mo) |
| MonumenTAL-8 NCT06550895 |
P2 | Active, not recruiting | Multiple Myeloma | 11 | 2027-08-26 (+10 mo) |
| EPIC NCT07217587 |
P3 | Recruiting | Myasthenia Gravis | 115 | 2027-09-28 |
| UNITED NCT05092269 |
P3 | Active, not recruiting | Crohn Disease; Colitis, Ulcerative | 159 | 2027-09-29 |
| MACARONI-23 NCT05923073 |
P3 | Recruiting | Crohn's Disease | 120 | 2027-10-27 |
| KLK2-PASenger NCT07225946 |
P3 | Recruiting | Prostatic Neoplasms, Castration-Resistant | 800 | 2027-11-19 |
| OrigAMI-3 NCT06750094 |
P3 | Recruiting | Colorectal Neoplasms | 700 | 2027-12-15 |
| FREESIA-3 NCT06533098 |
P3 | Recruiting | Thrombocytopenia, Neonatal Alloimmune | 50 | 2027-12-15 |
| TAILOR NCT05963074 |
P2 | Active, not recruiting | Leukemia, Lymphocytic, Chronic, B-Cell; Small Lymphocytic Lymphoma | 333 | 2027-12-15 (-9 mo) |
| TRI Pro NCT07589634 |
P2 | Recruiting | Multiple Myeloma | 230 | 2027-12-31 |
| ICONIC-UC NCT07196748 |
P3 | Active, not recruiting | Colitis, Ulcerative | 896 | 2028-01-14 |
| JNJ-101556143 NCT07906717 |
P3 | Recruiting | Prostatic Neoplasms | 400 | 2028-02-14 |
| AmiNA NCT07586202 |
P2 | Recruiting | Carcinoma, Non-Small-Cell Lung | 68 | 2028-03-02 |
| Erdafitinib Intravesical Delivery System NCT05316155 |
P1/2 | Active, not recruiting | Non-Muscle Invasive Bladder Neoplasms | 235 | 2028-03-30 (+36 mo) |
| MoonRISe-3 NCT06919965 |
P3 | Recruiting | Non-Muscle Invasive Bladder Neoplasms | 220 | 2028-04-06 (+8 mo) |
| CARTITUDE-10 NCT07149857 |
P2 | Recruiting | Multiple Myeloma | 60 | 2028-04-12 (+3 mo) |
| DUET ENCORE-CD NCT07577843 |
P3 | Recruiting | Crohn Disease | 460 | 2028-06-12 |
| MoonRISe-1 NCT06319820 |
P3 | Recruiting | Non-Muscle Invasive Bladder Neoplasms | 641 | 2028-06-28 |
| DUET ENCORE-UC NCT07577856 |
P3 | Recruiting | Colitis, Ulcerative | 644 | 2028-08-11 |
| JNJ-101556143 Formulation 1 NCT06800313 |
P1/2 | Recruiting | Metastatic Prostate Cancer | 190 | 2028-08-17 (+18 mo) |
| KLK2-comPAS NCT07164443 |
P3 | Recruiting | Metastatic Castration-resistant Prostatic Neoplasms | 1203 | 2028-08-18 (+3 mo) |
| Seltorexant NCT07573176 |
P3 | Recruiting | Depressive Disorder, Major | 600 | 2028-08-24 |
| ICONIC-CD NCT07196722 |
P2/3 | Recruiting | Crohn Disease | 1092 | 2028-09-19 |
| CHARGE NCT07499232 |
P3 | Recruiting | Crohn Disease | 530 | 2028-11-15 |
| KaRAnaSa NCT07227025 |
P1/2 | Recruiting | Carcinoma, Non-Small-Cell Lung | 60 | 2028-11-30 |
| GARDENIA-SLE NCT07438496 |
P3 | Recruiting | Lupus Erythematosus, Systemic | 600 | 2028-12-06 |
| TRIlogy-4 NCT07258511 |
P3 | Recruiting | Multiple Myeloma | 400 | 2028-12-12 |
| OrigAMI-2 NCT06662786 |
P3 | Recruiting | Colorectal Neoplasms | 1000 | 2028-12-15 |
| Esketamine 56 mg NCT07716098 |
P3 | Recruiting | Depressive Disorder, Treatment-Resistant | 348 | 2028-12-27 |
| cAMeLot-1 NCT04811560 |
P1/2 | Recruiting | Acute Leukemia | 420 | 2028-12-29 (+60 mo) |
| Daratumumab NCT05438043 |
P3 | Active, not recruiting | Multiple Myeloma | 214 | 2029-01-31 (+36 mo) |
| CARTITUDE-5 NCT04923893 |
P3 | Active, not recruiting | Multiple Myeloma | 743 | 2029-02-14 (+37 mo) |
| TRIlogy-5 NCT07518186 |
P3 | Recruiting | Multiple Myeloma | 700 | 2029-04-29 |
| JNJ-101556143 NCT07832292 |
P2 | Recruiting | Prostatic Neoplasms | 100 | 2029-05-17 |
| COPERNICUS NCT06667076 |
P2 | Recruiting | Carcinoma, Non-Small-Cell Lung | 480 | 2029-05-23 |
| OrigAMI-5 NCT07276399 |
P3 | Recruiting | Squamous Cell Carcinoma of Head and Neck | 600 | 2029-06-18 |
| cAMeLot-2 NCT06852222 |
P3 | Recruiting | Leukemia, Myeloid, Acute | 600 | 2029-06-22 |
| JNJ-81201887 NCT06635148 |
P2/3 | Recruiting | Geographic Atrophy; Macular Degeneration | 274 | 2029-08-24 |
| READY-BREATHE NCT07746687 |
P2 | Recruiting | Asthma | 440 | 2029-09-11 |
| SunRISe-3 NCT05714202 |
P3 | Active, not recruiting | Bladder Cancer | 1135 | 2029-09-18 (-8 mo) |
| FREESIA-1 NCT06449651 |
P3 | Recruiting | Thrombocytopenia, Neonatal Alloimmune | 39 | 2029-12-05 |
| Talisman NCT06500884 |
P2 | Recruiting | Multiple Myeloma | 210 | 2030-05-30 (+49 mo) |
| aMMbition NCT06577025 |
P2 | Active, not recruiting | Multiple Myeloma | 43 | 2030-09-02 (+1 mo) |
| TRIlogy-7 NCT07665450 |
P3 | Recruiting | Multiple Myeloma | 1000 | 2030-09-04 |
| SunRISe-5 NCT06211764 |
P3 | Active, not recruiting | Non-Muscle Invasive Bladder Neoplasms | 272 | 2030-11-27 |
| AVENUE NCT07227454 |
P3 | Recruiting | Depressive Disorder, Major | 258 | 2031-04-09 |
| MajesTEC-7 NCT05552222 |
P3 | Recruiting | Multiple Myeloma | 1590 | 2031-04-30 (+21 mo) |
| TRILOGY NCT06663332 |
P3 | Recruiting | Crohns Disease; Colitis, Ulcerative | 196 | 2031-12-12 |
| OrigAMI-4 NCT06385080 |
P1/2 | Recruiting | Squamous Cell Carcinoma of Head and Neck | 287 | 2032-12-27 (+77 mo) |
| TRIlogy-6 NCT07903272 |
P3 | Not yet recruiting | Multiple Myeloma | 1000 | 2037-01-11 |
| JNJ-90014496 NCT05421663 |
P1/2 | Active, not recruiting | Lymphoma, Non-Hodgkin; Lymphoma, B-Cell | 166 | 2041-07-30 |